Linked Data API

Show Search Form

Search Results

100887
registered interest false more like this
date less than 2014-10-24more like thismore than 2014-10-24
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Asthma more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211918 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100721
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Osteoporosis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211732 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100723
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Motor Neurone Disease: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211734 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100728
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Motor Neurone Disease more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211730 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100730
registered interest false more like this
date less than 2014-10-23more like thismore than 2014-10-23
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Osteoporosis: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years. more like this
tabling member constituency Leicester West more like this
tabling member printed
Liz Kendall more like this
uin 211735 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-29more like thismore than 2014-10-29
answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-29T17:12:28.3318918Zmore like thismore than 2014-10-29T17:12:28.3318918Z
question first ministerially corrected
less than 2014-11-13T10:22:56.0372213Zmore like thismore than 2014-11-13T10:22:56.0372213Z
answering member
4020
label Biography information for George Freeman more like this
previous answer version
25123
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
answering member
4020
label Biography information for George Freeman more like this
tabling member
4026
label Biography information for Liz Kendall more like this
100092
registered interest false more like this
date less than 2014-10-21more like thismore than 2014-10-21
answering body
Department for Business, Innovation and Skills more like this
answering dept id 26 more like this
answering dept short name Business, Innovation and Skills more like this
answering dept sort name Business, Innovation and Skills more like this
hansard heading Zero Hours Contracts more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Business, Innovation and Skills, what steps he is taking to help workers on zero hours contracts who desire regular, contracted employment. more like this
tabling member constituency Coventry South more like this
tabling member printed
Mr Jim Cunningham more like this
uin 211362 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-27more like thismore than 2014-10-27
answer text <p>Under the Flexible Working Regulations, brought in on 30 June, all employees with 26 continuous weeks of service have the right to request flexible working from their employer. Individuals on zero hours contracts, who are employees, can request a change in their contracts, which could also include a request to move to a fixed hours contract.</p><p> </p> more like this
answering member constituency East Dunbartonshire more like this
answering member printed Jo Swinson more like this
question first answered
less than 2014-10-27T14:48:39.5462303Zmore like thismore than 2014-10-27T14:48:39.5462303Z
answering member
1513
label Biography information for Jo Swinson more like this
tabling member
308
label Biography information for Mr Jim Cunningham more like this
93497
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Ministry of Defence more like this
answering dept id 11 more like this
answering dept short name Defence more like this
answering dept sort name Defence more like this
hansard heading Tornado Aircraft: Safety Measures more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Defence, what progress his Department has made on (a) the Tornado TCAS trials at BAE Warton and (b) the embodiment programme for the Tornado fleet as a whole. more like this
tabling member constituency Moray more like this
tabling member printed
Angus Robertson more like this
uin 210783 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-24more like thismore than 2014-10-24
answer text <p>Flight trials of the Traffic Alert and Collision Avoidance System II in two Tornado aircraft during 2014 have revealed a number of issues that require resolution before the system can be rolled-out across the fleet. It is not possible to give an indication of revised timescales until the scope of the additional work has been properly assessed.</p> more like this
answering member constituency Ludlow more like this
answering member printed Mr Philip Dunne more like this
question first answered
less than 2014-10-24T13:27:42.6728574Zmore like thismore than 2014-10-24T13:27:42.6728574Z
answering member
1542
label Biography information for Philip Dunne more like this
previous answer version
23772
answering member constituency Ludlow more like this
answering member printed Mr Philip Dunne more like this
answering member
1542
label Biography information for Philip Dunne more like this
tabling member
1433
label Biography information for Angus Robertson more like this
92526
registered interest false more like this
date less than 2014-10-10more like thismore than 2014-10-10
answering body
Department for Energy and Climate Change more like this
answering dept id 63 more like this
answering dept short name Energy and Climate Change more like this
answering dept sort name Energy and Climate Change more like this
hansard heading Solar Power: Renewables Obligation more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Energy and Climate Change, whether the Renewables Obligation for sub-5mW solar will be reviewed or consulted on before May 2015. more like this
tabling member constituency Sunderland Central more like this
tabling member printed
Julie Elliott more like this
uin 209292 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-15more like thismore than 2014-10-15
answer text <p>Our recent consultation confirmed our policy that solar PV for projects of 5MW and below will continue. We continue to monitor the Renewables Obligation solar PV deployment pipeline for projects of 5MW and below. As indicated in our recent government response to the consultation on changes to financial support for solar PV<sup>1</sup>, if this monitoring indicates that deployment is growing more rapidly than can be afforded, we will consider taking measures to protect the Levy Control Framework. Any such proposals would require further consultation.</p><p><em><strong>[1]</strong></em><em> <a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/360280/Government_response_RO-FIT_changes_to_Solar_PV_-_FINAL_2014-10-02.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/360280/Government_response_RO-FIT_changes_to_Solar_PV_-_FINAL_2014-10-02.pdf</a></em></p><p> </p> more like this
answering member constituency West Suffolk more like this
answering member printed Matthew Hancock more like this
question first answered
less than 2014-10-15T13:55:33.4773397Zmore like thismore than 2014-10-15T13:55:33.4773397Z
answering member
4070
label Biography information for Matt Hancock more like this
tabling member
4127
label Biography information for Julie Elliott more like this
91410
registered interest false more like this
date less than 2014-09-10more like thismore than 2014-09-10
answering body
Department for Education more like this
answering dept id 60 more like this
answering dept short name Education more like this
answering dept sort name Education more like this
hansard heading Local Safeguarding Children Boards more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Education, who is responsible for monitoring the effectiveness of child sexual exploitation action plans by local safeguarding children's boards. more like this
tabling member constituency East Worthing and Shoreham more like this
tabling member printed
Tim Loughton more like this
uin 209052 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-13more like thismore than 2014-10-13
answer text <p>Ofsted undertakes a review of each local safeguarding children’s board (LSCB) at the same time as they undertake their inspection of local authorities’ services for children in need of help and protection and looked after children. Neither the review nor the inspection makes specific judgements about the sexual exploitation of children or the effectiveness of the local child sexual exploitation action plans. However, inspectors are required to include in the cases they evaluate “children at risk of harm from physical, emotional and sexual abuse and neglect; inspectors will also want to identify those children and young people where the local authority have concerns that they may be vulnerable to child sexual exploitation and those children and young people who have been missing from care, home and education”. In undertaking the LSCB review inspectors are required to “evaluate the quality and impact of the policies and procedures produced by the LSCB, such as the local thresholds document and the child sexual exploitation action plan.” An LSCB’s response to child sexual exploitation is considered as part of the overall judgement on the performance of the LSCB. Seven LSCBs of the 3<ins class="ministerial">3</ins><del class="ministerial">1</del> inspected since the new framework came into being in November 2013 have been found to be inadequate.</p>
answering member constituency Crewe and Nantwich more like this
answering member printed Mr Edward Timpson more like this
question first answered
less than 2014-10-13T16:12:11.21Zmore like thismore than 2014-10-13T16:12:11.21Z
question first ministerially corrected
less than 2014-10-20T16:41:22.6005788Zmore like thismore than 2014-10-20T16:41:22.6005788Z
answering member
1605
label Biography information for Edward Timpson more like this
previous answer version
21507
answering member constituency Crewe and Nantwich more like this
answering member printed Mr Edward Timpson more like this
answering member
1605
label Biography information for Edward Timpson more like this
tabling member
114
label Biography information for Tim Loughton more like this
91483
registered interest false more like this
date less than 2014-09-10more like thismore than 2014-09-10
answering body
Department for Education more like this
answering dept id 60 more like this
answering dept short name Education more like this
answering dept sort name Education more like this
hansard heading Local Safeguarding Children Boards more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Education, who is responsible for monitoring the effectiveness of local safeguarding children boards' child sexual exploitation action plans. more like this
tabling member constituency East Worthing and Shoreham more like this
tabling member printed
Tim Loughton more like this
uin 209003 more like this
answer
answer
is ministerial correction true more like this
date of answer less than 2014-10-13more like thismore than 2014-10-13
answer text <p>Ofsted undertakes a review of each local safeguarding children’s board (LSCB) at the same time as they undertake their inspection of local authorities’ services for children in need of help and protection and looked after children. Neither the review nor the inspection makes specific judgements about the sexual exploitation of children or the effectiveness of the local child sexual exploitation action plans. However, inspectors are required to include in the cases they evaluate “children at risk of harm from physical, emotional and sexual abuse and neglect; inspectors will also want to identify those children and young people where the local authority have concerns that they may be vulnerable to child sexual exploitation and those children and young people who have been missing from care, home and education”. In undertaking the LSCB review inspectors are required to “evaluate the quality and impact of the policies and procedures produced by the LSCB, such as the local thresholds document and the child sexual exploitation action plan.” An LSCB’s response to child sexual exploitation is considered as part of the overall judgement on the performance of the LSCB. Seven LSCBs of the 3<ins class="ministerial">3</ins><del class="ministerial">1</del> inspected since the new framework came into being in November 2013 have been found to be inadequate.</p>
answering member constituency Crewe and Nantwich more like this
answering member printed Mr Edward Timpson more like this
question first answered
less than 2014-10-13T16:12:11.21Zmore like thismore than 2014-10-13T16:12:11.21Z
question first ministerially corrected
less than 2014-10-20T16:41:22.6005788Zmore like thismore than 2014-10-20T16:41:22.6005788Z
answering member
1605
label Biography information for Edward Timpson more like this
previous answer version
21592
answering member constituency Crewe and Nantwich more like this
answering member printed Mr Edward Timpson more like this
answering member
1605
label Biography information for Edward Timpson more like this
tabling member
114
label Biography information for Tim Loughton more like this